PBAC
Extended prescribing impasse
Mixed messages from the Department of Health over two-month prescriptions, as new documents say pharmacist mark-ups will impact consumer and taxpayer savings New Department of Health documents reveal that two-month …
‘Jobs will be lost.’
Pharmacy group estimates average loss of $85k in gross profit per pharmacy if 60-day dispensing proposal goes forward With the 60-day dispensing proposal still on the table, the Rural Pharmacy …
Dosing on the agenda
Decision on PPI double dosing deferred by PBAC, but support given to antibiotic listing changes The Pharmaceutical Benefits Advisory Committee (PBAC) has deferred a decision on whether to allow twice …
Still on the wish list
Are two month prescriptions back on the government’s agenda? Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) that prescription lengths be doubled to two months for a range of medicines …
Keeping up to date
PBAC reveals the latest raft of new recommendations made on PBS drugs The latest recommendations made by the Pharmaceutical Benefits Advisory Committee have been released, with new listings for naloxone …
Blockbuster alert
Nine new blockbuster drugs headed our way soon: report A series of new ‘blockbuster’ drugs are expected to hit Australian shores in the next 12-24 months, a new report claims. …
PrEP listing decision deferred
An HIV prevention advocate has vowed to keep fighting for pre exposure prophylaxis to be PBS listed Following the announcement by the Pharmaceutical Benefits Advisory Committee that it will defer …
CHF get a new seat on PBAC
Consumers’ group deputy head now gains a senior role on key PBS committee Federal Health Minister Greg Hunt has announced that Jo Watson, deputy chair of the Consumers Health Forum …
Warning on biosimilar burden
A higher than usual degree of pharmacovigilance is required when patients are switched to new biosimilar medications, say Australian experts Writing in the latest Australian Prescriber two pharmacy academics have stressed …
Use of warfarin is in decline
But NOACs have contributed to an overall growth in the anticoagulant market Based on the volume of prescriptions, use of novel oral anticoagulants (NOACs) in Australia has grown since their …
Panadol Osteo decision could shift patients to opioids
Stakeholders have expressed disappointment in the PBAC’s restatement of its decision to delist Panadol Osteo, and concerns that patients may turn to stronger alternatives to manage their pain. The PBAC …
Panadol Osteo, admit it was a mistake: Guild
It is time the government ‘fessed up’ that Panadol Osteo has been de-listed from the PBS by mistake, says the Guild today. It says that in April last year PBAC set very clear criteria …